Patents Assigned to Sloan Kettering Institute
-
Patent number: 10548998Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.Type: GrantFiled: June 15, 2018Date of Patent: February 4, 2020Assignees: Sloan-Kettering Institute for Cancer Research, Cornell UniversityInventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason S. Lewis, Steven M. Larson
-
Patent number: 10537561Abstract: The present invention provides a compound of formula I; wherein R1 is an alkyl pyrazole or an alkyl carboxamide, and R2 is a hydroxycycloalkyl; or a pharmaceutically acceptable salt thereof, and compositions containing these compounds, for use to treat a brain tumor, particularly glioblastoma. The invention provides effective treatment of a brain tumor and can be used by oral administration of a compound of Formula I as further described herein. The invention also provides a method to treat a subject having a brain tumor such as glioblastoma, wherein the method comprises administering to the subject an effective amount of a compound of Formula I. Gene signatures correlated with successful treatment using these methods are also disclosed.Type: GrantFiled: June 4, 2018Date of Patent: January 21, 2020Assignees: Novartis AG, Sloan-Kettering Institute for Cancer ResearchInventors: Dylan Daniel, Johanna Joyce, James Sutton
-
Patent number: 10526310Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3,4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.Type: GrantFiled: April 15, 2019Date of Patent: January 7, 2020Assignees: Aragon Pharmaceuticals Inc., Sloan Kettering Institute for Cancer ResearchInventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
-
Patent number: 10406236Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: GrantFiled: April 24, 2017Date of Patent: September 10, 2019Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Patent number: 10336757Abstract: Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are other wise delivered to the brain.Type: GrantFiled: July 2, 2007Date of Patent: July 2, 2019Assignees: Sloan-Kettering Institute for Cancer Research, The Rockefeller UniversityInventors: Gabriela Chiosis, Paul Greengard, Fei Dou, Wenjie Luo, Huazhong He, Danuta Zatorska
-
Patent number: 10322194Abstract: The present disclosure, among other things, provides a composition including a nanoscale core; a plurality of capping agent entities associated on the core; an outer encapsulant layer; and a plurality of dopant entities distributed at locations selected from the group consisting of: on or within the nanoscale core, on or between capping agent entities, on or within the encapsulating layer, and combinations thereof. Provided technologies can achieve unprecedented levels of dopant entity density and/or surface localization, which, for a SE(R)RS-active agent dopant, results in dramatically improved signal intensity and/or imaging sensitivity.Type: GrantFiled: August 30, 2013Date of Patent: June 18, 2019Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Moritz Kircher, Stefan Harmsen, Matthew Wall
-
Patent number: 10314815Abstract: The present invention provides a crystalline Form A of Compound 1, also referred to as Granaticin B, and pharmaceutically compositions thereof. The present invention also provides methods of treating a microbial infection, or a disease, disorder, or condition associated with abnormal cellular proliferation, using crystalline Form A of Compound 1 or pharmaceutical compositions thereof.Type: GrantFiled: December 22, 2015Date of Patent: June 11, 2019Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventor: Tero Kunnari
-
Patent number: 10308630Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.Type: GrantFiled: May 9, 2018Date of Patent: June 4, 2019Assignees: Sloan-Kettering Institute for Cancer Research, Aragon Pharmaceuticals, Inc.Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
-
Patent number: 10307479Abstract: This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.Type: GrantFiled: October 31, 2016Date of Patent: June 4, 2019Assignee: Sloan-Kettering Institute for Cancer ResearchInventor: Nai-Kong V. Cheung
-
Patent number: 10286057Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a vaccine for HIV-1, comprising synthetic V3 glycopeptides, and to methods of making and using same.Type: GrantFiled: April 15, 2014Date of Patent: May 14, 2019Assignees: Duke University, Sloan-Kettering Institute for Cancer Research, Dana-Farber Cancer Institute, Inc.Inventors: Barton F. Haynes, Hua-xin Liao, Samuel Danishefsky, Peter Park, Joseph Sodroski, Baptiste Aussedat, Yusuf Vohra
-
Publication number: 20190046538Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.Type: ApplicationFiled: February 27, 2018Publication date: February 14, 2019Applicants: Sloan Kettering Institute for Cancer Research, Board of Regents, The University of Texas SystemInventors: Jimmy Andrew ROTOLO, Richard N. KOLESNICK, Renata PASQUALINI, Wadih ARAP
-
Patent number: 10172863Abstract: The present application provides substituted purine derivatives and related compounds of the formulas shown. These compounds are useful as inhibitors of HSP90, and hence in the treatment of related diseases. (Formulae) Z1-Z3, Xa-Xc, X2, X4, Y and R are as defined in the specification.Type: GrantFiled: April 21, 2016Date of Patent: January 8, 2019Assignee: Sloan-Kettering Institute For Cancer ResearchInventors: Gabriela Chiosis, Tony Taldone, Weilin Sun
-
Patent number: 10150775Abstract: Compounds of formula: in which R4 is chosen from substituted phenyl, optionally substituted naphthylene, optionally substituted anthracene and optionally substituted aromatic heterocycle, are useful as analgesics.Type: GrantFiled: August 8, 2017Date of Patent: December 11, 2018Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Gavril Pasternak, Susruta Majumdar
-
Patent number: 10123992Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: GrantFiled: October 10, 2017Date of Patent: November 13, 2018Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Publication number: 20180305426Abstract: The present invention provides pluripotent and multipotent stem cells, including embryonic stem cells, induced pluripotent stem cells, adult stem cells and other progenitor cells, that have been modified to contain an inducible cancer-specific suicide gene construct that, upon induction, selectively kills stem- or progenitor-cell-derived cancerous cells without significant effect on healthy tissues or other (noncancerous) cells derived from such cells. This suicide gene construct expresses a dominant negative MYC-interfering protein (D-MIP) that acts as a tumor suppressor in cancer cells without significant deleterious effects on healthy cells and tissues. The suicide gene construct can also be used in gene therapies that produce cancers arising in association with the presence of the gene therapy vector and likewise discriminates between killing of cancerous cells and non-cancerous cells modified with a gene therapy vector.Type: ApplicationFiled: January 2, 2018Publication date: October 25, 2018Applicant: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Elisa Oricchio, Hans-Guido Wendel
-
Patent number: 10105456Abstract: The present disclosure, among other things, provides a composition of a particle including a substrate; at least a first condensation layer comprising at least a first dopant entity; and at least a second layer comprising a second dopant entity. In some embodiments, different dopant entities are included in different layers. In some embodiments, such dopant entities are or comprise detectable entities. This, in some embodiments, provided technologies achieve multi-modality particles. Among the many advantages of provided technologies include the ability to image particles by a plurality of distinct imaging modalities and/or in a plurality of contexts (e.g., pre-surgical, intraoperative and/or post-surgical environments).Type: GrantFiled: December 19, 2013Date of Patent: October 23, 2018Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Stefan Harmsen, Matthew Wall, Moritz Kircher
-
Publication number: 20180258386Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.Type: ApplicationFiled: February 27, 2018Publication date: September 13, 2018Applicants: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer ResearchInventors: Shahin RAFII, Fan ZHANG, Marco SEANDEL
-
Patent number: 10064867Abstract: The disclosure relates to Compounds of Formula (1): and pharmaceutically acceptable salts thereof wherein Z1, Z2, Z3, Xa, Xb, Xc, Y, X2, and X4 are as defined herein, compositions comprising an effective amount of a Compound of Formula (1) or a pharmaceutically acceptable salt thereof, and methods to treat or prevent a condition, such as cancer which overexpresses Her-kinases, comprising administering to an patient in need thereof a therapeutically effective amount of a Compound of Formula (1) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 9, 2016Date of Patent: September 4, 2018Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Tony Taldone, Gabriela Chiosis
-
Patent number: 9999694Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.Type: GrantFiled: March 17, 2014Date of Patent: June 19, 2018Assignees: Sloan-Kettering Institute for Cancer Research, Cornell UniversityInventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason S. Lewis, Steven M. Larson
-
Patent number: 10000494Abstract: Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands.Type: GrantFiled: July 25, 2016Date of Patent: June 19, 2018Assignee: Sloan-Kettering Institute for Cancer ResearchInventor: Gabriela Chiosis